AGIO Stock — Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. (AGIO)

Updated October 16, 2026.

AGIO is a Stock. Total return is 0.1% over the past 13.2 years, 466.1 points behind SPY at 466.2%.

Agios Pharmaceuticals is a biopharmaceutical company discovering and developing medicines targeting cellular metabolism, with a focus on rare blood disorders. Its lead product, PYRUKYND, treats hemolytic anemias caused by pyruvate kinase deficiency in adults and is in late-stage testing for sickle cell disease and pediatric applications; the company also markets AQVESME for thalassemia and has other candidates in development for conditions including myelodysplastic syndrome and phenylketonuria. The company does not currently distribute dividends, making it oriented toward growth-focused investors rather than income seekers.

AGIO performance versus SPY

Price and return data through 2026-10-16.

Total return is 0.1% over the past 13.2 years, 466.1 points behind SPY at 466.2%. Over the past year its total return — price change plus distributions reinvested — is -24.6%. Its deepest 1-year drawdown was 50.9%.

AGIO key facts

Asset type

Stock

Asset class

Equity

Inception date

07/24/2013

Distribution frequency

None

Last close

$31.32 (as of 2026-10-16)

Market cap

$1,869,862,944

Average volume

952660.0

Beta

0.63

Payout ratio

0.0%

Forward P/E

2.4655

EPS

$-7.01

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AGIO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 50.9%.

Who may consider AGIO — and who may not

It is a weaker fit for investors who need monthly cash flow (AGIO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AGIO

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions